INVESTMENTS IN INNOVATION

QNBV

Promentis Pharmaceuticals, Inc.

Biosciences/Medical Devices

826 N. Plankinton Avenue Suite 400
Milwaukee, 53203-1804
United States

Promentis Pharmaceuticals, Inc. is developing novel compounds for the treatment of central nervous system disorders. Promentis’ drug development efforts are focused on the neurotransmitter glutamate, oxidative stress, and their critical role in the pathophysiology of schizophrenia, autism and selected rare, pediatric diseases that affect the brain.